Commentary|Articles|August 27, 2026

Reading CKM Signals Together: A Pharmacist's Guide

Author(s)Andrew Bzowyckyj, PharmD, BCPS, CDCES, FADCES, FAPhA, FCCP, Luke Halpern, Associate Editor

Andrew Bzowyckyj, PharmD, explains how pharmacists can use albuminuria, ejection fraction, and inflammation to drive earlier CKM risk stratification and patient care.

In an interview with Pharmacy Times, Andrew Bzowyckyj, PharmD, BCPS, CDCES, FADCES, FAPhA, FCCP, senior scientific director and learning consultant at the National Kidney Foundation (NKF), discussed how the cardiovascular-kidney-metabolic (CKM) syndrome framework helps pharmacists evaluate patients comprehensively. The discussion was based on his presentation at the 2026 Association of Diabetes Care and Education Specialists (ADCES) Annual Meeting in Columbus, Ohio.